Industry

Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual Meeting

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented final results from the Phase II SUMMIT ‘basket’ trial, assessing the efficacy of neratinib in treatment-refractory patients with metastatic biliary tract cancers with somatic HER2 mutations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation entitled “Targeting HER2 mutation-positive advanced … [Read more…]

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma

28-month, median follow-up data from the CARTITUDE-1 study of cilta-cel in patients with relapsed or refractory multiple myeloma presented at the 2022 ASCO Annual meeting Overall response rate remains at 98 percent after more than two years, with median progression-free and overall survival not yet being reached Results from Cohorts A and B of the … [Read more…]

Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress

Overall Response Rate (ORR) of 60% Observed in Patients with Relapsed or Refractory (R/R) EBV+ PTLD Consistent with Previously Reported Studies Completion of All Pre-Approval Inspections Required to Support EU Marketing Authorization Application; Anticipated European Commission Approval On-Track for Q4 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, … [Read more…]

Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma (LBCL)

— Patients Aged 65+ Had Over Three-fold Improvement in Two-year Event-Free Survival (EFS) Rate, and Over Eight-fold Greater Median EFS and Clinically Meaningful Improvements in Quality of Life (QoL) with Yescarta vs SOC — — Separate Exploratory Analysis Found Yescarta Benefit vs SOC Was Consistent Across Subgroups, Including in Patients with High Tumor Burden and … [Read more…]

Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients

– At One Year, 3X as Many Patients Were Progression-Free Compared to Physicians’ Choice of Chemotherapy in Phase 3 TROPiCS-02 Study – – At The First Interim Analysis, Overall Survival Demonstrated a Positive Trend, Patients Will Continue to be Followed – – Analysis of Patient-Reported Outcomes Shows Trodelvy Also Improved Quality of Life over Physicians’ … [Read more…]

Circulating Tumor DNA Guides Chemotherapy Use in Stage II Colon Cancer

Researchers from TGen, a part of City of Hope, contribute to study supporting value of ctDNA in assessing treatment options PHOENIX–(BUSINESS WIRE)–Tumor DNA circulating in the bloodstream can help clinicians decide whether chemotherapy is right for their patients who have undergone surgery for stage II colon cancer, according to a breakthrough study published online in … [Read more…]

Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced overall survival (OS) results from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE® (palbociclib) in combination with letrozole compared to placebo plus letrozole for the first-line treatment of postmenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). With a median … [Read more…]

Sparrow Pharmaceuticals Presents New Pharmacological Data on HSD-1 Inhibitor SPI-62 at the 2022 Annual European Congress of Rheumatology

Results indicate that SPI-62 has the potential to mitigate adverse effects of glucocorticoid medications PORTLAND, Ore.–(BUSINESS WIRE)–Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both rheumatology and endocrinology, today presented new animal model data during an in-person poster session titled, “Toward Safer Glucocorticoid Therapy of Polymyalgia Rheumatica” … [Read more…]

At Prides, AHF Invites All Communities to #StandAgainstHate

On the heels of divisive and dangerous ‘Don’t Say Gay’ bills targeting LGBTQ+ individuals and families in Florida, Ohio and other states and as LGBTQ+ Pride seasons kick off, AHF will take part in a dozen Prides and parades nationwide, with messaging that #We Stand United and must #StandAgainstHate Since 2021, 42 states have considered … [Read more…]

Biomarkers May Predict Better Immunotherapy Treatment Outcomes for Certain Patients with Pancreatic Cancer

Findings from the Parker Institute for Cancer Immunotherapy (PICI) and its collaborative network of researchers, including from the University of Pennsylvania, presented at 2022 ASCO Annual Meeting and published in Nature Medicine New data from the PRINCE clinical trial, co-funded by PICI, Bristol Myers Squibb and the Cancer Research Institute in collaboration with Apexigen, could … [Read more…]